Good morning and welcome to Bausch + Lomb’s Third Quarter 2024 Earnings Call. [Operator Instructions] Please note this event ...

Banks and private credit firms are competing to provide at least $5 billion of debt financing to help fund a potential buyout ...

The potential sale of its 88% stake in Bausch + Lomb could generate billions for creditors and shareholders of the indebted ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price ...

Bausch + Lomb scaled up its revenue guidance for the year after swinging to a profit in the latest quarter on the back of sales growth in each of its business segments.

H.C. Wainwright analyst Yi Chen raised the firm’s price target on Bausch + Lomb (BLCO) to $23 from $22 and keeps a Buy rating on the ...

Net income attributable to Bausch + Lomb Corporation for the third quarter of 2024 was $4 million, as compared to a net loss of $84 million for the third quarter of 2023, a favorable change of $88 ...

including Bausch + Lomb contact lens brands such as Bausch + Lomb INFUSE®, Bausch + Lomb ULTRA® and Biotrue® ONEday. Over-the-counter products will include LUMIFY® redness reliever eye drops ...

Bausch + Lomb is recognized for its innovative contact lens portfolio, including its popular ULTRA brand and advanced surgical equipment offerings, driven by its premium IOL portfolio. To fully ...

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care ...

Cathleen McCabe, MD has joined Bausch + Lomb as strategic medical advisor. Palvella Therapeutics named Matthew E. Korenberg ...